Insider · CIK 0001450324
Thomas K Equels
Files at AIM (AIM ImmunoTech Inc.). First filing Nov 27, 2023, latest Sep 18, 2026.
In brief
Thomas K Equels files SEC Form 4 as CEO, president and director at AIM (AIM ImmunoTech Inc.). Since Nov 27, 2023, Thomas K Equels has reported 16 open-market buys worth $141k and 0 open-market sells worth $0, the latest filed on Sep 18, 2026.
After Thomas K Equels's past buys, the stock trailed the S&P 500 by a median 66.9% over six months (n = 11), and 0% of those buys were ahead of the index at six months. InsiderTell labels that a negative record.
The newest scored trade: bought $4,992 of AIM on Sep 17, 2026, filed Sep 18, 2026, scored 54 (moderate). In the last 12 months: 4 buys worth $13k and 0 sells worth $0.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
AIM: AIM ImmunoTech Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 54Moderate | AIMbuy AIM ImmunoTech Inc. | $4,992 24,000 shares | +23% | +5% from low-92% from high | |
| 51Moderate | AIMbuy AIM ImmunoTech Inc. | $2,310 11,000 shares | +12% | 0% from low-92% from high | |
| 54Moderate | AIMbuy AIM ImmunoTech Inc. | $4,862 22,000 shares | +32% | 0% from low-92% from high | |
| 46Moderate | AIMbuy AIM ImmunoTech Inc. | $1,292 5,900 shares | +9% | 0% from low-92% from high | |
| 33Weak | AIMbuy AIM ImmunoTech Inc. | $824 107 shares | +0% | +123% from low-78% from high | |
| 33Weak | AIMbuy AIM ImmunoTech Inc. | $896 103 shares | +0% | +179% from low-73% from high | |
| 80Strong | AIM ImmunoTech Inc. | $50k 1,968,504 shares | +104% | 0% from low-90% from high | |
| 63Notable | AIM ImmunoTech Inc. | $2,583 41,000 shares | +2% | 0% from low-71% from high | |
| 48Moderate | AIMbuy AIM ImmunoTech Inc. | $6,730 50,000 shares | +3% | +8% from low-58% from high | |
| 48Moderate | AIMbuy AIM ImmunoTech Inc. | $5,060 44,000 shares | +2% | 0% from low-61% from high | |
| 48Moderate | AIMbuy AIM ImmunoTech Inc. | $10k 83,334 shares | +5% | 0% from low-61% from high | |
| 46Moderate | AIM ImmunoTech Inc. | $4,240 20,000 shares | +1% | +17% from low-32% from high | |
| 30Weak | AIMbuy AIM ImmunoTech Inc. | $4,682 22,727 shares | +1% | - | |
| 44Moderate | AIM ImmunoTech Inc. | $17k 85,000 shares | +5% | +11% from low-35% from high | |
| 41Moderate | AIM ImmunoTech Inc. | $11k 60,110 shares | +4% | +11% from low-35% from high | |
| 36Weak | AIMbuy AIM ImmunoTech Inc. | $15k 33,861 shares | +6% | +39% from low-44% from high |
Transactions
Every row this insider has filed, 20 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 17, 2026 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +24,000 | $0.21 | $4,992 | 126,822 | 25 d ago |
| Sep 16, 2026 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +11,000 | $0.21 | $2,310 | 102,822 | 26 d ago |
| Sep 15, 2026 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +22,000 | $0.22 | $4,862 | 91,822 | 27 d ago |
| Sep 14, 2026 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +5,900 | $0.22 | $1,292 | 69,822 | 28 d ago |
| Mar 12, 2026 | AIM AIM ImmunoTech Inc. | CConversion Common stock | +25,000 | $0.00 | $0 | 63,922 | Mar 16, 2026 |
| Mar 12, 2026 | AIM AIM ImmunoTech Inc. | CConversion Series G Convertible Preferred Stockderivative | -25 | $0.00 | $0 | 0 | Mar 16, 2026 |
| Mar 6, 2026 | AIM AIM ImmunoTech Inc. | JOther Series G Convertible Preferred Stockderivative | +25 | $25,000.00 | $625k | 25 | Mar 10, 2026 |
| Mar 6, 2026 | AIM AIM ImmunoTech Inc. | JOther Class G Warrantsderivative | +50,000 | $0.00 | $0 | 50,000 | Mar 10, 2026 |
| Jun 13, 2025 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +107 | $7.70 | $824 | 38,885 | Jun 16, 2025 |
| Jun 12, 2025 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +103 | $8.70 | $896 | 38,675 | Jun 13, 2025 |
| Apr 11, 2025 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +1,968,504 | $0.03 | $50k | 3,867,533 | Apr 23, 2025 |
| Apr 4, 2025 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +41,000 | $0.06 | $2,583 | 1,899,029 | Apr 7, 2025 |
| Mar 5, 2025 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +50,000 | $0.13 | $6,730 | 1,858,029 | Mar 6, 2025 |
| Mar 4, 2025 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +44,000 | $0.12 | $5,060 | 1,808,029 | Mar 5, 2025 |
| Mar 4, 2025 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +83,334 | $0.12 | $10k | 1,764,029 | Mar 4, 2025 |
| Nov 21, 2024 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +20,000 | $0.21 | $4,240 | 1,657,968 | Jan 21, 2025 |
| Dec 18, 2024 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +22,727 | $0.21 | $4,682 | 1,680,695 | Dec 19, 2024 |
| Nov 20, 2024 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +85,000 | $0.20 | $17k | 1,637,968 | Nov 21, 2024 |
| Nov 20, 2024 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +60,110 | $0.18 | $11k | 1,552,968 | Nov 20, 2024 |
| Nov 27, 2023 | AIM AIM ImmunoTech Inc. | POpen-market purchase Common Stock | +33,861 | $0.44 | $15k | 640,697 | Nov 27, 2023 |
Questions about Thomas K Equels
Answered from the filings on this page, as of the latest one.
Is Thomas K Equels buying or selling?
In the last 12 months Thomas K Equels reported 4 open-market buys worth $13k and 0 open-market sells worth $0 on SEC Form 4; the latest was bought $4,992 of AIM on Sep 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Thomas K Equels's past buys perform?
Measured from the first close after each filing, the stock trailed the S&P 500 by a median 66.9% over six months across 11 past buys, with 0% ahead of the index. Past results describe what happened; they do not predict the next trade.
Where does Thomas K Equels file Form 4?
Thomas K Equels has filed Form 4 at AIM (AIM ImmunoTech Inc.) as CEO & President. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.